Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
450 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05926960 | A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma(PORTSIDE) | terminated | Phase 2 | 38 | PfizerINDUSTRY | 5 | Mar 9, 2026 | clinicaltrials |
| NCT07442838 | Clinical Outcomes and Complications in Two-stage Breast Reconstruction Using Microtextured and Nanotextured Expanders(RA-IBBR-NvsM) | active not recruiting | — | 88 | Comenius UniversityOTHER |
| 1 |
| Mar 3, 2026 |
| clinicaltrials |
| NCT01602380 | A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.(FALCON) | completed | Phase 3 | 462 | AstraZenecaINDUSTRY | 20 | Feb 27, 2026 | clinicaltrials |
| NCT01909453 | Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma(COLUMBUS) | completed | Phase 3 | 921 | PfizerINDUSTRY | 29 | Feb 27, 2026 | clinicaltrials |
| NCT00699751 | A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases(ALSYMPCA) | completed | Phase 3 | 921 | BayerINDUSTRY | 19 | Feb 23, 2026 | clinicaltrials |
| NCT05909397 | Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer(VERITAC-3) | active not recruiting | Phase 3 | 59 | PfizerINDUSTRY | 10 | Feb 10, 2026 | clinicaltrials |
| NCT05419388 | A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma | completed | Phase 2 | 93 | Hoffmann-La RocheINDUSTRY | 10 | Feb 4, 2026 | clinicaltrials |
| NCT02246621 | A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer(MONARCH 3) | active not recruiting | Phase 3 | 493 | Eli Lilly and CompanyINDUSTRY | 22 | Feb 3, 2026 | clinicaltrials |
| NCT02003924 | Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer(PROSPER) | completed | Phase 3 | 1,401 | PfizerINDUSTRY | 32 | Jan 27, 2026 | clinicaltrials |
| NCT07298252 | Diagnostic Accuracy of Carebot AI MMG in Mammography Screening: Multicenter MRMC Study(CARE-MMG-MRMC) | completed | — | 222 | Carebot s.r.o.INDUSTRY | 2 | Jan 14, 2026 | clinicaltrials |
| NCT03869892 | Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.(SOLSTICE) | active not recruiting | Phase 3 | 856 | Institut de Recherches Internationales ServierOTHER | 25 | Dec 22, 2025 | clinicaltrials |
| NCT03997123 | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC(CAPItello-290) | active not recruiting | Phase 3 | 923 | AstraZenecaINDUSTRY | 30 | Dec 22, 2025 | clinicaltrials |
| NCT03774082 | Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant(REACH 5) | completed | Phase 2 | 46 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 11, 2025 | clinicaltrials |
| NCT03760003 | Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis | completed | Phase 2 | 355 | Abivax S.A.INDUSTRY | 17 | Nov 28, 2025 | clinicaltrials |
| NCT04003610 | Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) | terminated | Phase 2 | 7 | Incyte CorporationINDUSTRY | 16 | Nov 4, 2025 | clinicaltrials |
| NCT02677896 | A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)(ARCHES) | completed | Phase 3 | 1,150 | Astellas Pharma Global Development, Inc.INDUSTRY | 24 | Oct 24, 2025 | clinicaltrials |
| NCT02367040 | Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)(CHRONOS-3) | completed | Phase 3 | 458 | BayerINDUSTRY | 37 | Oct 14, 2025 | clinicaltrials |
| NCT02514447 | Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy | completed | Phase 1 / Phase 2 | 123 | G1 Therapeutics, Inc.INDUSTRY | 8 | Sep 25, 2025 | clinicaltrials |
| NCT06082167 | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(STELLAR-305) | active not recruiting | Phase 2 / Phase 3 | 600 | ExelixisINDUSTRY | 26 | Aug 17, 2025 | clinicaltrials |
| NCT00005584 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma | active not recruiting | Phase 3 | 1,649 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Aug 5, 2025 | clinicaltrials |
| NCT01776840 | A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 523 | Janssen Research & Development, LLCINDUSTRY | 28 | Jul 8, 2025 | clinicaltrials |
| NCT00981058 | First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin(SQUIRE) | completed | Phase 3 | 1,093 | Eli Lilly and CompanyINDUSTRY | 26 | Jun 18, 2025 | clinicaltrials |
| NCT04734444 | SonoClear Acoustic Coupling Fluid (ACF) Mimicking Brain Tissue | completed | N/A | 45 | SonoClear ASINDUSTRY | 3 | Jun 17, 2025 | clinicaltrials |
| NCT03390686 | A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients | active not recruiting | Phase 3 | 650 | Prestige Biopharma LimitedINDUSTRY | 17 | May 31, 2025 | clinicaltrials |
| NCT06958783 | Chemotherapy-induced Lipid Profile Changes in Women With Early Breast Cancer | completed | — | 56 | Cancer center Stefan Kukura Hospital MichalovceOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT04691284 | Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation(SCTMICROBIOM) | recruiting | N/A | 100 | National Cancer Institute, SlovakiaOTHER_GOV | 1 | May 29, 2025 | clinicaltrials |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | terminated | Phase 1 | 85 | PfizerINDUSTRY | 5 | May 28, 2025 | clinicaltrials |
| NCT03551626 | Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes(COMBI-APlus) | completed | Phase 3 | 552 | Novartis PharmaceuticalsINDUSTRY | 23 | Apr 29, 2025 | clinicaltrials |
| NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis(LIVERATION) | recruiting | Phase 3 | 471 | Can-Fite BioPharmaINDUSTRY | 9 | Apr 29, 2025 | clinicaltrials |
| NCT03643276 | Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 | recruiting | Phase 3 | 5,000 | Martin SchrappeOTHER | 8 | Apr 6, 2025 | clinicaltrials |
| NCT05790304 | Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects | completed | Phase 1 | 22 | AstraZenecaINDUSTRY | 3 | Mar 25, 2025 | clinicaltrials |
| NCT00490139 | ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D(ALTTO) | completed | Phase 3 | 8,381 | Novartis PharmaceuticalsINDUSTRY | 44 | Mar 21, 2025 | clinicaltrials |
| NCT00353496 | Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours(CLARINET) | completed | Phase 3 | 264 | IpsenINDUSTRY | 15 | Mar 5, 2025 | clinicaltrials |
| NCT05829629 | Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women | recruiting | Phase 1 | 20 | BlueSky Immunotherapies GmbHINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT03358875 | Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)(RATIONALE-303) | completed | Phase 3 | 805 | BeiGeneINDUSTRY | 10 | Feb 10, 2025 | clinicaltrials |
| NCT00104676 | Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors | completed | Phase 3 | 263 | UNICANCEROTHER | 3 | Feb 6, 2025 | clinicaltrials |
| NCT01715285 | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | completed | Phase 3 | 1,209 | Janssen Research & Development, LLCINDUSTRY | 33 | Feb 4, 2025 | clinicaltrials |
| NCT02576574 | Avelumab in First-line NSCLC (JAVELIN Lung 100) | completed | Phase 3 | 1,214 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 42 | Jan 31, 2025 | clinicaltrials |
| NCT06529302 | The OPBC-07/microNAC Study | active not recruiting | — | 2,000 | University Hospital, Basel, SwitzerlandOTHER | 30 | Jan 24, 2025 | clinicaltrials |
| NCT02990338 | Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients(ICARIA-MM) | completed | Phase 3 | 307 | SanofiINDUSTRY | 24 | Jan 17, 2025 | clinicaltrials |
| NCT03709680 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | active not recruiting | Phase 2 | 128 | PfizerINDUSTRY | 14 | Jan 14, 2025 | clinicaltrials |
| NCT06292988 | Predictive Factors for Medullary Thyroid Cancer Aggressiveness(MYELO) | completed | — | 500 | Aristotle University Of ThessalonikiOTHER | 24 | Jan 3, 2025 | clinicaltrials |
| NCT03836261 | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL(AMPLIFY) | active not recruiting | Phase 3 | 984 | Acerta Pharma BVINDUSTRY | 27 | Dec 27, 2024 | clinicaltrials |
| NCT03673306 | Safety of Pregnancy in BRCA Mutated Breast Cancer Patients | completed | — | 4,732 | Jules Bordet InstituteOTHER | 26 | Dec 13, 2024 | clinicaltrials |
| NCT02626455 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)(CHRONOS-4) | terminated | Phase 3 | 551 | BayerINDUSTRY | 35 | Dec 11, 2024 | clinicaltrials |
| NCT03994211 | Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer | completed | Phase 1 | 25 | BeiGeneINDUSTRY | 4 | Oct 26, 2024 | clinicaltrials |
| NCT03191786 | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy(IPSOS) | completed | Phase 3 | 453 | Hoffmann-La RocheINDUSTRY | 24 | Oct 23, 2024 | clinicaltrials |
| NCT03240523 | A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 5) | terminated | Phase 3 | 766 | BayerINDUSTRY | 23 | Oct 18, 2024 | clinicaltrials |
| NCT03154827 | Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML) | terminated | Phase 1 / Phase 2 | 1 | BioLineRx, Ltd.INDUSTRY | 6 | Sep 5, 2024 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials